Toth Financial Advisory Corp Increases Stake in Medtronic PLC $MDT

Toth Financial Advisory Corp lifted its position in Medtronic PLC (NYSE:MDT) by 8.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 74,270 shares of the medical technology company’s stock after acquiring an additional 5,863 shares during the quarter. Toth Financial Advisory Corp’s holdings in Medtronic were worth $7,134,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Corundum Trust Company INC bought a new position in Medtronic during the 3rd quarter worth about $27,000. Lodestone Wealth Management LLC bought a new stake in shares of Medtronic in the 4th quarter valued at about $27,000. Board of the Pension Protection Fund purchased a new stake in shares of Medtronic in the 4th quarter worth approximately $29,000. GoalVest Advisory LLC purchased a new stake in shares of Medtronic in the 4th quarter worth approximately $29,000. Finally, Valley Wealth Managers Inc. bought a new position in shares of Medtronic during the third quarter valued at approximately $29,000. 82.06% of the stock is owned by hedge funds and other institutional investors.

Medtronic Stock Performance

Shares of MDT opened at $86.61 on Friday. The company has a current ratio of 2.54, a quick ratio of 1.87 and a debt-to-equity ratio of 0.57. The firm has a market cap of $111.19 billion, a PE ratio of 24.12, a P/E/G ratio of 2.24 and a beta of 0.75. Medtronic PLC has a 12 month low of $79.55 and a 12 month high of $106.33. The stock has a fifty day moving average price of $94.47 and a 200-day moving average price of $96.22.

Medtronic (NYSE:MDT) last announced its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, topping the consensus estimate of $1.34 by $0.02. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The firm had revenue of $9.02 billion for the quarter, compared to the consensus estimate of $8.89 billion. During the same period in the previous year, the business earned $1.38 EPS. The firm’s revenue for the quarter was up 5.8% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities research analysts predict that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 17th. Stockholders of record on Friday, March 27th will be paid a dividend of $0.71 per share. The ex-dividend date is Friday, March 27th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.3%. Medtronic’s payout ratio is presently 79.11%.

Insider Activity

In other news, EVP Harry Skip Kiil sold 52,524 shares of the company’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the transaction, the executive vice president owned 32,768 shares in the company, valued at $3,201,761.28. This represents a 61.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.26% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

MDT has been the topic of several research reports. Leerink Partners reissued an “outperform” rating and set a $119.00 price objective on shares of Medtronic in a report on Tuesday, March 10th. Sanford C. Bernstein increased their target price on Medtronic from $111.00 to $112.00 and gave the company an “outperform” rating in a research report on Friday, January 9th. JPMorgan Chase & Co. cut their price target on Medtronic from $105.00 to $100.00 and set a “neutral” rating on the stock in a report on Wednesday, February 18th. UBS Group reissued a “neutral” rating and issued a $104.00 price target on shares of Medtronic in a research report on Wednesday, February 4th. Finally, Daiwa Securities Group decreased their price objective on Medtronic from $117.00 to $115.00 and set a “buy” rating for the company in a research note on Friday, February 27th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have assigned a Hold rating to the stock. According to data from MarketBeat, Medtronic presently has an average rating of “Moderate Buy” and an average price target of $109.85.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter?defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).